Tsukasa Shibue

Tsukasa Shibue

Auto-generated profile, based on publicly available information

Tsukasa Shibue

Broad Institute of MIT and Harvard, Cambridge, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2024 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
RARand Arafeh
Rand Arafeh
TSTsukasa Shibue
Tsukasa Shibue
JDJoshua M. Dempster
Joshua M. Dempster
WHWilliam C. Hahn
William C. Hahn
FVFrancisca Vazquez
Francisca Vazquez

28 December 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
LCLisa D. Cervia
Lisa D. Cervia
TSTsukasa Shibue
Tsukasa Shibue
ABAshir A. Borah
Ashir A. Borah
BGBenjamin Gaeta
Benjamin Gaeta
LHLinh He
Linh He
WHWilliam C. Hahn
William C. Hahn
Systematic identification of signaling pathways required for the fitness of cancer cells will facilitate the development of new cancer therapies. We used gene essentiality measurements in 1,086 cancer cell lines to identify selective coessentiality modules and found that a ubiquitin ligase complex composed of UBA6, BIRC6, KCMF1, and UBR4 is required for the survival of a subset of epithelial tumors that exhibit a high degree of aneuploidy. Suppressing BIRC6 in cell lines that are dependent on this complex led to a substantial reduction in cell fitness in vitro and potent tumor regression in vivo. Mechanistically, BIRC6 suppression resulted in selective activation of the integrated stress response (ISR) by stabilization of the heme-regulated inhibitor, a direct ubiquitination target of the UBA6/BIRC6/KCMF1/UBR4 complex. These observations uncover a novel ubiquitination cascade that regulates ISR and highlight the potential of ISR activation as a new therapeutic strategy. Significance: We describe the identification of a heretofore unrecognized ubiquitin ligase complex that prevents the aberrant activation of the ISR in a subset of cancer cells. This provides a novel insight on the regulation of ISR and exposes a therapeutic opportunity to selectively eliminate these cancer cells. See related commentary Leli and Koumenis, p. 535. This article is highlighted in the In This Issue feature, p. 517

10 July 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
GWGregory P. Way
Gregory P. Way
MKMaria Kost-Alimova
Maria Kost-Alimova
TSTsukasa Shibue
Tsukasa Shibue
WHWilliam F. Harrington
William F. Harrington
SGStanley Gill
Stanley Gill
SSShantanu Singh
Shantanu Singh
Genetic and chemical perturbations impact diverse cellular phenotypes, including multiple indicators of cell health. These readouts reveal toxicity and antitumorigenic effects relevant to drug discovery and personalized medicine. We developed two customized microscopy assays, one using four targeted reagents and the other three targeted reagents, to collectively measure 70 specific cell health phenotypes including proliferation, apoptosis, reactive oxygen species (ROS), DNA damage, and cell cycle stage. We then tested an approach to predict multiple cell health phenotypes using Cell Painting, an inexpensive and scalable image-based morphology assay. In matched CRISPR perturbations of three cancer cell lines, we collected both Cell Painting and cell health data. We found that simple machine learning algorithms can predict many cell health readouts directly from Cell Painting images, at less than half the cost. We hypothesized that these trained models can be applied to accurately predict cell health assay outcomes for any future or existing Cell Painting dataset. For Cell Painting images from a set of 1,500+ compound perturbations across multiple doses, we validated predictions by orthogonal assay readouts, and by confirming mitotic arrest, ROS, and DNA damage phenotypes via PLK, proteasome, and aurora kinase/tubulin inhibition, respectively. We provide an intuitive web app to browse all predictions at http://broad.io/cell-health-app . Our approach can be used to add cell health annotations to Cell Painting perturbation datasets.

5 August 2026 in Nature
Verified
Journal Article
Open access
PDF file
JNJames V. Neiswender
James V. Neiswender
SMSamuel Maffa
Samuel Maffa
LBLisa Brenan
Lisa Brenan
DEDina ElHarouni
Dina ElHarouni
YYYejie Yun
Yejie Yun
FVFrancisca Vazquez
Francisca Vazquez
Despite advances in precision oncology, effective personalized treatments are still lacking for most patients with cancer1. The Cancer Dependency Map (DepMap) accelerates this field by systematically identifying cancer vulnerabilities in diverse preclinical models. Data from over 1,300 cell lines have led to the discovery of new therapeutic strategies across multiple tumour types2. However, mapping cancer vulnerabilities using traditional cell lines has limitations, including insufficient cancer subtype representation and the impact of culture conditions on perturbation responses. Here we perform 147 genome-scale CRISPR screens and multi-omic characterizations of next-generation (NextGen) cancer models (organoids and spheroids) across 10 cancer types. This strategy enables the expansion of DepMap to cover new genomic and molecular subtypes and to identify new biomarker-associated vulnerabilities. These new models also preserve transcriptional programs that are silenced in traditional cell lines and facilitate the discovery of specific gene dependencies associated with these programs. Comparisons of traditional and NextGen cancer models enable further identification of distinct effects of growth format and culture medium on gene essentiality. The integrated dataset combines data from both model types to offer a valuable, expansive resource for exploring cancer vulnerabilities and is accessible via the DepMap portal.

26 March 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
AWAllison Warren
Allison Warren
AJAndrew Jones
Andrew Jones
TSTsukasa Shibue
Tsukasa Shibue
WHWilliam C. Hahn
William C. Hahn
JBJesse S. Boehm
Jesse S. Boehm
JMJames M. McFarland
James M. McFarland
Cell lines are key tools for preclinical cancer research, but it remains unclear how well they represent patient tumor samples. Identifying cell line models that best represent the features of particular tumor samples, as well as tumor types that lack in vitro model representation, remain important challenges. Gene expression has been shown to provide rich information that can be used to identify tumor subtypes, as well as predict the genetic dependencies and chemical vulnerabilities of cell lines. However, direct comparisons of tumor and cell line transcriptional profiles are complicated by systematic differences, such as the presence of immune and stromal cells in tumor samples and differences in the cancer-type composition of cell line and tumor expression datasets. To address these challenges, we developed an unsupervised alignment method (Celligner) and applied it to integrate several large-scale cell line and tumor RNA-Seq datasets. While our method aligns the majority of cell lines with tumor samples of the same cancer type, it also reveals large differences in tumor/cell line similarity across disease types. Furthermore, Celligner identifies a distinct group of several hundred cell lines from diverse lineages that present a more mesenchymal and undifferentiated transcriptional state and which exhibit distinct chemical and genetic dependencies. This method could thus be used to guide the selection of cell lines that more closely resemble patient tumors and improve the clinical translation of insights gained from cell line models.